Tourmaline Bio (TRML) said Tuesday its Tranquility phase 2 trial assessing monthly and quarterly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein, or hs-CRP, showed "rapid, deep and durable" reductions in hs-CRP levels through day 90.
Tranquility is a multicenter, randomized, double-blind, placebo-controlled phase 2 trial in patients with elevated hs-CRP, a biomarker associated with elevated cardiovascular risk and chronic kidney disease, and CKD stage 3 or 4. A total of 143 participants were enrolled in the trial, and 126 participants comprised the primary analysis population.
The company said the trial is the starting point of the clinical development program for pacibekitug, an anti-IL-6 monoclonal antibody developed by the company, to treat atherosclerotic cardiovascular disease and other cardiovascular diseases.
The trial results support the progress of pacibekitug into a planned phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease and support pacibekitug's advancement into a planned phase 2 proof-of-concept trial in abdominal aortic aneurysm, the company said.
Shares of the company were down more than 11% in recent Tuesday trading.
Price: 13.74, Change: -2.89, Percent Change: -17.38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.